New eye injection aims to control wet AMD with fewer doses

NCT ID NCT07587515

Not yet recruiting Disease control Sponsor: Eyconis INC. Source: ClinicalTrials.gov ↗

First seen May 20, 2026 · Last updated May 20, 2026

Summary

This early-stage study tests the safety of an experimental drug called EYC-0305 in 30 adults aged 50 and older with wet age-related macular degeneration (AMD). Participants receive an injection into the eye every 24 weeks. The goal is to see if the drug is safe and tolerable, and to check how it affects vision and disease activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bellaire, TX

Bellaire, Texas, 77401, United States
Beverly Hills, CA

Beverly Hills, California, 90211, United States
Erie, PA

Erie, Pennsylvania, 16505, United States
McAllen, TX

McAllen, Texas, 78503, United States
The Woodlands, TX

The Woodlands, Texas, 77384, United States

Conditions

Explore the condition pages connected to this study.

NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION